Market News
Recent Developments
New product launches
- Evusheld (tixagevimab and cilgavimab) by AstraZeneca, one of the global pharmaceutical company: This antibody cocktail was approved by the U.S.FDA in December 2021 for the prevention of COVID-19 in adults who are at high risk of severe disease.
- Sotrovimab by Vir Biotechnology: This antibody was approved by the U.S.FDA in October 2021 for the treatment of mild to moderate COVID-19 in adults who are at high risk of progression to severe disease.
- REGEN-COV2 (casirivimab and imdevimab) by Regeneron Pharmaceuticals and Rocheone of the leading healthcare company: This antibody cocktail was approved by the U.S.FDA in November 2020 for the treatment of mild to moderate COVID-19 in adults who are at high risk of progression to severe disease.
Acquisition and partnerships
- In September 2021, Sanofi, one of the leading pharmaceutical company acquired Translate Bio for US$3.20 billion. Translate Bio is a gene therapy company that develops treatments for rare diseases using neutralizing antibodies.
- In September 2020, Gilead Sciences, a research-based biopharmaceutical company acquired Immunomedics for US$21.00 billion. Immunomedics is a clinical-stage biopharmaceutical company that develops antibody-drug conjugates (ADCs).
- In October 2020, IAVI, a nonprofit scientific research organization, Serum Institute of India Pvt. Ltd., a leading manufacturer of vaccines and biologics and Merck KGaA, a leading science and technology company, announced their partnership and agreement to develop SARS-CoV-2 neutralizing monoclonal antibodies (mAbs) co-invented by IAVI and Scripps Research as innovative interventions to address the COVID-19 pandemic.
U.S.: 
U.K. : 
India : 
